Skip to main content
Clinical Trials/NL-OMON52660
NL-OMON52660
Recruiting
Not Applicable

Clinical trial to evaluate safety and efficacy of the C2 CryoBalloon 180° Ablation System for the treatment of dysplastic Barrett*s esophagus: CBAS180 de-escalation study - CBAS180 de-escalation study

Pentax Medical0 sites122 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Barrett's esophagus
Sponsor
Pentax Medical
Enrollment
122
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Flat type BE esophagus, with an indication for ablation therapy, defined as:
  • a) Diagnosis of LGD or HGD in BE (confirmed by BE expert pathologist) or;
  • b) Residual BE with any grade of dysplasia after endoscopic resection (by means
  • of EMR or ESD) to treat non\-flat BE, \>\=6 weeks prior to enrolling the patient to
  • this study. The ER pathology should indicate endoscopic treatment (i.e. only
  • mucosal invasion or limited submucosal invasion (sm1\), no lymphovascular
  • infiltration, free vertical resection margins and not poorly differentiated).
  • 2\) Prague Classification Score of C\<\=3 and M\>\=1\.
  • 3\) Patients should be ablation\-naïve, meaning they have not undergone any
  • previous endoscopic ablation therapy of the esophagus.

Exclusion Criteria

  • 1\) Esophageal stenosis preventing advancement of a therapeutic endoscope.
  • 2\) Any endoscopically visualized lesion such as ulcers, masses or nodules.
  • Neoplastic nodules must first be treated with ER \>\=6 weeks prior to planned
  • treatment under this protocol.
  • 3\) Prior ER of \>2cm in length and/or \>50% of the esophageal lumen
  • circumference.
  • 4\) History of locally advanced (\>sm1\) esophageal cancer.
  • 5\) History of esophageal varices.
  • 6\) Prior distal esophagectomy.
  • 7\) Active esophagitis LA grade B or higher.

Outcomes

Primary Outcomes

Not specified

Similar Trials